Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 14, 2017. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions were executed on July 13, 2017, on the London Stock Exchange.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transaction data:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.2649 per share for all reported transactions.
- Transaction Nature: Acquisition of shares following the re-investment of dividends paid on July 13, 2017.
Material Changes
The filing does not report material changes to the company's financial position or operations. It reports routine compliance disclosures regarding the increase in shareholdings of nine specific executives and one associated person due to dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Important Facts for Investors
- Transaction Type: All reported acquisitions were automatic reinvestments of dividends, not open-market purchases funded by personal capital.
- Participants: Transactions involved senior leadership including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and Presidents of Global Vaccines, Global Pharmaceuticals, R&D, and Global Manufacturing & Supply.
- Share Volume: Individual share acquisitions ranged from approximately 16 shares (Mr S A Hussain) to 2,338 shares (Dr P J T Vallance).
- Market Price: The transactions confirm the share price was £16.2649 on July 13, 2017.